Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil
Efficacy in Alzheimer’s Disease Patients Page 1 Journal of Alzheimer’s Disease 30 (2012) …

Objective Cytochrome P450 (CYP) 2D6 enzyme is the major responsible for the metabolism
of donepezil, an inhibitor of acetyl cholinesterase currently used for the symptomatic …

Objective The aims of this study were to evaluate the impact of the CYP2D6 polymorphism
on both the steady-state plasma concentrations (Cp) and the clinical outcome of donepezil …

Background: Donepezil is one of the most commonly prescribed drugs for the treatment of
Alzheimer disease. It is predominantly metabolized through CYP2D6 and to a lesser extent …

Background/purpose Donepezil was approved for the treatment of Alzheimer's disease (AD)
but causes variable therapeutic responses. Thus, identifying specific genetic …

Background The aim of this study was to evaluate the effect of CYP2D6* 10 and APOE
polymorphisms on both steady-state plasma concentrations (Cp) and clinical response of …

Aims A large interindividual variability in plasma concentrations has been reported in
patients treated with donepezil, the most frequently prescribed antidementia drug. We aimed …

Dementia is a syndrome of global and progressive deterioration of cognitive skills,
especially memory, learning, abstract thinking, and orientation, usually affecting the elderly …

Objective: To evaluate the influence of the single nucleotide polymorphism rs1080985 in the
cytochrome P450 2D6 (CYP2D6) gene on the efficacy of donepezil in patients with mild to …

Background Recent data indicate that the rs1080985 single nucleotide polymorphism of the
cytochrome P450 (CYP) 2D6 gene may affect the response to treatment with donepezil in …